GSK chooses insider to lead consumer healthcare spin-off post separation

Current head of the consumer healthcare division appointed to steer spin-off after planned separation.


On Thursday, the British pharma giant confirmed the current head of its consumer healthcare division, Brian McNamara, will stay at the helm of the business following its spin-off next year. As detailed during GSK's Investor Update on 23 June 2021, the division will be listed on the London Stock Exchange following its separation from the pharma business next year. The entity will house a portfolio which generated sales of more than £10 billion last year, and will sell well-known brands such as Sensodyne, Voltaren, Panadol and Centrum. GSK has been under pressure from Elliot Management, which has pushed for change at the company and also indicated a preference for Emma Walmsley, who ran the consumer unit before being promoted to chief executive, to take over the reigns.


McNamara began his career at P&G and held a variety of roles across product supply, brand marketing, and customer leadership over a 16-year period before joining Novartis in 2004, where he also headed up the Over the Counter (OTC) division. He joined GSK in 2015 and was instrumental in the formation of the JV between GSK and Pfizer, that created the Consumer Healthcare business he’s been leading. "I am honoured to have this opportunity. Together with the many talented people we have in our business, I am looking forward to our exciting future as an independent company. I am confident we are well positioned for growth, building on our brands and innovation, with leading-edge science and human understanding, to deliver better everyday health.", said the CEO Designate.